1. Overnight Market Performance - Domestic commodity futures market closed with widespread gains, precious metals, shipping futures, new energy materials, and base metals rose significantly, Shanghai silver rose 14.42%, the container shipping index (European line) rose 11.3%, and Shanghai tin hit the daily limit [4][43] - International precious metal futures generally closed higher, COMEX gold futures rose 2.40% to $4608.80 per ounce, COMEX silver futures rose 7.33% to $85.16 per ounce [5][45] - The main contract of US crude oil closed up 1.22% at $59.84 per barrel; the main contract of Brent crude oil rose 1.41% to $64.23 per barrel [6][45] - London base metals all rose, LME tin rose 5.47% to $48,200.0 per ton, LME nickel rose 2.12% to $18,075.0 per ton, etc [6][45] 2. Important News 2.1 Macroeconomic News - China and the EU will provide general guidance on price commitments to Chinese exporters of pure electric vehicles to the EU [9] - As of January 12, 2026, the Shanghai Export Container Settlement Freight Index (European route) was 1956.39 points, up 8.9% from the previous period [10] - Trump denied participating in the Justice Department's subpoena of the Federal Reserve [10] - The Guangzhou Futures Exchange called on market participants to strengthen risk prevention [10] 2.2 Energy and Chemical Futures - As of the week ending January 12, domestic asphalt social inventory increased by 2.4% week - on - week and 26.7% year - on - year [12] - As of January 12, domestic soda ash manufacturers' total inventory decreased by 0.51% from the previous Thursday [14] - From January 2 - 8, the operating rate of Chinese LOW - E glass sample enterprises remained stable [15] - As of January 12, the MEG inventory in the East China main port area increased by 4.7 tons from the previous period [15] 2.3 Metal Futures - The Shanghai Gold Exchange warned of significant price fluctuations in precious metals [17] - Nearly 50% of lithium - battery enterprises expect lithium carbonate prices to exceed 200,000 yuan by April 1 [17] - Australia plans to buy and stockpile key minerals [17] - On January 12, the price of spodumene forward spot rose [17] - On January 12, the market transaction price of battery - grade lithium fluoride rose by 10,000 yuan per ton [19] 2.4 Black - Series Futures - The Dalian Commodity Exchange solicited opinions on adjusting the inspection method for iron ore delivery quality standards [21] - From January 5 - 11, the arrival volume of iron ore at 47 ports in China increased, while the global iron ore shipping volume decreased [21] - Last week, the coking coal online auction failure rate dropped to a two - month low [21] - Handan launched a level - II emergency response for heavy pollution weather on January 12 [22] 2.5 Agricultural Product Futures - In the 2025/26 season, China's soybean production was slightly adjusted, with an expected output of 20.91 million tons [25] - Malaysia's palm oil export volume from January 1 - 10 increased, while production decreased [25] - As of January 7, the hog - to - corn ratio was 5.51, up 2.04% from December 31, 2025 [26] - Malaysia's palm oil inventory in December increased by 7.58% month - on - month [26] - Brazilian soybean harvest rate as of last Thursday was 0.6% [27] - As of January 8, the US soybean export inspection volume was 1.529707 million tons [27] - The 2025/26 global soybean production is expected to increase by 3.1 million tons [28] - The US corn production in 2025/26 is expected to increase [28] 3. Financial Markets 3.1 Financial Sector - A - share commercial space concept stocks and AI concept stocks issued risk warnings [30] - Hong Kong stocks rose, with the Hang Seng Index up 1.44% [30] - Fund companies adjusted the operation mechanisms of precious - metal - related funds [30] - Brain - computer interface company Strong Brain Technology secretly submitted a Hong Kong IPO application [31] - XPeng's flying car division submitted a confidential Hong Kong IPO application [32] 3.2 Industrial Sector - The global memory chip industry is in a price - rising cycle, and packaging and testing manufacturers have raised prices [34] - Tianjin will manage the sales prices of new commercial housing [34] - The Mars sample return mission of NASA and ESA was cancelled [34] - The Lihong - 1 aircraft completed its first sub - orbital flight test [34] - Tianjin University completed the first "space brain - computer interface experiment" [35] - A 630℃ power unit generator rotor was successfully installed [35] - Five types of original special cosmetics need to be re - registered as ordinary cosmetics [37] - Banks launched "asset improvement activities" [37] - In 2025, global smartphone shipments increased by 2% year - on - year [37] 3.3 Overseas Markets - Trump imposed a 25% tariff on countries doing business with Iran [38] - Trump warned of huge compensation if the US Supreme Court made an unfavorable tariff ruling [38] - The UK and Germany are discussing deploying troops in Greenland [38] - India's PSLV rocket failed in a launch [38] - US, European, and Asia - Pacific stock markets showed different trends [40][41] - The US House Republicans are promoting a bill to ban insider trading by congressmen [40] - South Korea plans to extend stock trading hours [42] 3.4 Commodity Markets - Domestic and international commodity futures markets generally rose [43][45] - The Guangzhou Futures Exchange restricted the trading of some clients in lithium carbonate futures [46] 3.5 Bond Markets - China's bond market strengthened, while US bond yields rose [47] 3.6 Foreign Exchange Markets - The on - shore RMB against the US dollar rose, and the RMB exchange rate index reached new highs [48] 4. Upcoming Economic Data and Events 4.1 Economic Data - Various economic data such as Japan's trade balance, UK's retail sales, and US CPI will be released [50] 4.2 Events - FOMC members and European Central Bank officials will give speeches [52] - Multiple conferences and expos will be held [52] - China's central bank has reverse repurchase maturities [52]

Domestic Market Overview - The domestic market experienced a steady rise, with the Shanghai Composite Index closing at 4165.29 points, up 1.09%, and the Shenzhen Component Index at 14366.91 points, up 1.75% [1][4][6] - The total trading volume of the A-share market reached 36,446 billion, showing an increase compared to the previous day [1][4][6] - Among the 30 sectors tracked, 26 saw gains, with media, computer, and defense industries leading the increase, while only oil, coal, real estate, and agriculture sectors experienced slight declines [1][4][6] Overseas Market Overview - The three major U.S. stock indices saw slight increases, with the Dow Jones up 0.17%, S&P 500 up 0.16%, and Nasdaq up 0.26% [2][4] - Chinese concept stocks surged, with the Nasdaq Golden Dragon China Index rising over 4%, and notable gains from companies like Kingsoft Cloud, which rose over 21%, and Alibaba, which increased by more than 10% [2][4] News Highlights - The Chinese government has issued its first systematic guidelines for the investment direction and layout of government investment funds, emphasizing alignment with national strategic planning and encouraging investment in key industries [8][9] - The successful maiden flight of the Lihong No. 1 spacecraft was reported, marking a significant achievement in space technology [11] - Ongoing discussions between China and the EU regarding electric vehicle trade have progressed, with both parties agreeing on the need for common guidelines for price commitments [12] Driving Factors - The Ministry of Industry and Information Technology announced initiatives to rejuvenate traditional industries and promote emerging sectors, focusing on breakthroughs in quantum technology, human-robot interfaces, and 6G technology [7] - A total of 4,144 stocks in the A-share market rose, with 863 stocks increasing by over 5%, indicating strong market enthusiasm [7]

Group 1 - The robot ETF (562500) has risen by 0.37%, showing strong trading activity with a turnover exceeding 9.20 billion yuan within the first hour of trading, indicating high market interest in the robotics sector [1] - Key stocks in the ETF include Optoelectronics, which has increased by over 1.6%, along with Dingzhi Technology, Aofeite-U, and Jiangsu Beiren, reflecting heightened activity among core upstream players in the industry [1] - The current market dynamics suggest a significant exchange of holdings, with investors remaining sensitive to the long-term value of the robotics sector, marking a potential window for observing future upward trends [1] Group 2 - The Ministry of Civil Affairs and seven other departments have introduced measures to promote the development of the elderly care service industry, emphasizing the integration of technology such as big data, cloud computing, and AI into elderly care [2] - The initiative encourages the development of elderly care robots to meet the daily care, emotional support, and social needs of the elderly, promoting collaboration across industries like robotics, medical rehabilitation, and smart home technology [2] - Support will be provided for the research and development of technologies such as exoskeleton robots and brain-machine interfaces to assist elderly individuals with declining physical functions, enhancing the overall technological support for elderly care [2] Group 3 - Macquarie Securities suggests that domestic humanoid robot manufacturers are likely to gain a competitive advantage during the mass production phase, recommending attention to these manufacturers and their supply chains [3] - The domestic market is identified as the best early-stage market for humanoid robots, with a well-established supply chain and a rich pool of high-quality labor, positioning domestic manufacturers favorably in international competition [3] - The robot ETF (562500) is the only robot-themed ETF in the market with a scale exceeding 20 billion yuan, covering various segments including humanoid robots, industrial robots, and service robots, facilitating investor access to the entire robotics industry chain [3]

Group 1 - The A-share market is experiencing increased divergence, with pharmaceuticals and insurance sectors leading in gains, while rare earth and photovoltaic sectors are undergoing significant adjustments. The medical device ETF (562600) has risen by 2.32%, marking its fourth consecutive day of gains, with its holding, Di'an Diagnostics, achieving three consecutive limit-up days [1] - Nvidia and Eli Lilly are set to jointly invest $1 billion over the next five years to establish an AI drug laboratory, focusing on advancing robotic technology and physical AI to accelerate medical discovery and production [1] - Huafu Securities anticipates that the start of the 14th Five-Year Plan will lead to more proactive fiscal signals, emphasizing opportunities in AI medical applications. The launch of "Ant Ai Fu" highlights the real demand for AI in healthcare, while the listing of companies like Zhizhu and miniMax indicates a new phase of capital acceleration [1] Group 2 - The medical device industry is rapidly developing, and investors can leverage the medical device ETF (562600) to capture growth opportunities. This ETF tracks the CSI All-Index Medical Device Index, with brain-computer interfaces accounting for 23.8%, the highest among listed ETFs, and the medical device sector comprising 89.2%, indicating a strong concentration that can effectively capture growth in niche markets [2] - For off-market users, options include the Huaxia CSI All-Index Medical Device ETF Initiated Link A (021250) and Huaxia CSI All-Index Medical Device ETF Initiated Link C (021251) for convenient investment [2]

半导体设备ETF（159516）跟踪的是半导体材料设备指数（931743），该指数聚焦于半导体产业中 的材料与设备领域，从市场中选取涉及半导体材料供应及设备制造的上市公司证券作为指数样本，以反 映半导体产业链上游相关企业的整体表现。该指数具有较高的科技含量和成长性特征，是投资者布局半 导体行业的重要参考工具。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构 成投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产 品要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 开源证券指出，电子和半导体行业在当前流动性宽松、政策支持及产业高景气的背景下，仍具备较 强的成长动能。全球半导体周期自2023年一季度启动以来已连续9个季度维持正增长，由GPU和生成式 AI驱动的需求展现出前所未有的结构性深度与资本开支韧性。通信设备（如光通信）受益于AI算力扩 张、数据中心扩容及智能汽车电子化升级，需求呈现类似5G基站建设期的结构性提升。尽管 ...

Group 1 - Nvidia and Eli Lilly will invest $1 billion over the next five years to establish an AI drug laboratory, focusing on accelerating medical discovery and production through robotics and physical AI [1] - The announcement has led to a significant rise in related pharmaceutical stocks, with Dean Diagnostics hitting the daily limit up for three consecutive trading days, and other companies like BGI Genomics and Berry Genomics seeing increases of over 16% and 8% respectively [1] - The medical device index ETF (159898) has gained 2.52% and has seen a net subscription of 366 million yuan over six consecutive days, indicating high market interest [1] Group 2 - Huafu Securities predicts that 2026 will mark the beginning of a new five-year period for AI healthcare, with expectations of more proactive fiscal signals supporting AI medical applications [2] - The current demand for AI applications in healthcare is expected to sustain the industry's long-term development, with recent events indicating a shift towards commercialization [2] - The National Medical Products Administration is expected to release ten measures by 2025-2026 to support the innovation and development of AI healthcare and high-end medical devices [2] Group 3 - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, focusing entirely on the A-share medical device sector, with a pure beta quality [3] - The top ten holdings of the index include leading companies like Mindray Medical and United Imaging Healthcare, with over 80% of the portfolio in the ChiNext and STAR Market [3] Group 4 - The ETF's index includes a significant focus on brain-computer interface concepts, which account for approximately 24% of the index [4] - There is a scarcity of pure brain-computer interface stocks in the A-share market, presenting opportunities for capturing innovation in the industry [4] Group 5 - The medical device sector, which includes brain-computer interfaces, is expected to see substantial demand before and during the initial production phase of these technologies [5]

Group 1 - The core viewpoint of the article highlights the long-term investment opportunities in the medical device sector, driven by innovation, international expansion, and mergers and acquisitions [1] - The medical device sector is experiencing a revaluation as its innovative and international capabilities gain recognition, with a focus on improved and breakthrough innovations that are becoming increasingly acknowledged [1] - By 2026, a turning point is expected in the medical device sector, with opportunities for performance and valuation recovery in individual stocks, particularly those related to overseas expansion and performance recovery [1] Group 2 - The article emphasizes the growing recognition of brain-computer interfaces and AI in healthcare, with significant catalysts in these areas, particularly in consumer health management and AI doctors [1] - The ETF mentioned, Guotai (159377), tracks the Chuangyi Medicine Index (399275), which includes companies with outstanding innovation capabilities and high R&D investment, reflecting the overall performance of high-growth pharmaceutical and biotechnology firms [1] - The medical device sector is anticipated to undergo a dual recovery in valuation and performance, with the potential for several stocks to experience significant growth in the context of a technology bull market [1]

Group 1 - The Hong Kong stock market has shown strong performance post-New Year, with the healthcare and pharmaceutical sectors exhibiting notable elasticity, as evidenced by the Hong Kong Stock Connect Medical ETF (520510) surging over 4% and achieving a year-to-date increase of over 20% [1] - The Hang Seng Medical ETF (159892) also experienced a year-to-date rise that once exceeded 17%, ranking among the top performers in the overall market ETFs [1] - Ark Health saw a significant increase of over 30% during trading, highlighting the robust interest in the healthcare sector [1] Group 2 - Zheshang Securities believes that the integration of AI and healthcare is flourishing, with policy support and market demand driving the industry into a rapid phase of commercialization [1] - In terms of AI healthcare applications, industry policies are clear and progress is swift, with five ministries issuing relevant implementation opinions by 2025, the launch of ChatGPT Health in early 2026, and Ant Group's Aifuku seeing monthly active users double to 30 million, all contributing to heightened market enthusiasm [1] - The Hong Kong Stock Connect Medical ETF (520510) tracks the Hong Kong Stock Connect Medical Theme Index, covering AI healthcare stocks such as Alibaba Health, JD Health, and Ping An Good Doctor, and is expected to benefit from advancements in brain-computer interfaces, innovative drug exports, and the AI healthcare technology revolution [1]

光大期货金融期货日报 光大期货金融期货日报（2026 年 01 月 13 日） 一、研究观点 | 品种 | 点评 | 观点 | | --- | --- | --- | | | 市场全天震荡走强，三大指数均涨超 1%，沪指走出 17 连阳。AI 应用方向全 | | | | 线爆发，蓝色光标、汉得信息等多股涨停。商业航天概念延续强势，中国卫 | | | | 星、中国卫通均涨停创新高。脑机接口概念反复活跃，道氏技术、岩山科技 | | | | 等涨停。个股涨多跌少，沪深京三市超 4100 股飘红，今日成交 3.64 万亿， | | | | 刷新 A 股单日成交额新纪录。截止收盘沪指涨 1.09%，深成指涨 1.75%，创 | | | | 业板指涨 1.82%。资金情绪继续高涨，据统计，宽基型 ETF12 月净申购 1100 | | | | 亿元，其中近 1020 亿元为 A500ETF。A500 指数长期与沪深 300 走势高度相 | | | | 关，相关系数超过 0.98，细微差别在于 A500 指数成长标的稍多，例如电力 | | | 股指 | 设备、电子等板块。在 A500ETF 获得大幅申购的同时，我们关注到 ...

Core Viewpoint - The Chinese innovative drug sector is experiencing significant growth, highlighted by the recent clinical advancements and strategic partnerships, indicating a positive long-term trend in the industry. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (南方, 159297) rose by 2.98%, with a turnover of 53.79 million yuan and a turnover rate of 3.2% [1] - Key stocks in the index, such as Rongchang Biopharmaceuticals, Sihuan Pharmaceutical, and Boan Biotechnology, saw substantial increases of 9.38%, 7.38%, and 6.71% respectively [1] Group 2: Clinical Developments - The GLP-1 class drug, Masitide, developed in China, achieved a milestone with two pivotal Phase III clinical studies published in the prestigious journal Nature on December 18, 2025, showcasing China's drug development capabilities [1] Group 3: Strategic Partnerships - Rongchang Biopharmaceuticals announced an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with tiered royalties on net sales outside Greater China [1] Group 4: Industry Trends - Guosen Securities noted the explosive growth in business development (BD) transactions within the Chinese innovative drug industry, emphasizing that for many domestic innovative drugs, external licensing is just the starting point for global development [2] - The Hong Kong pharmaceutical sector has shown strong performance, particularly in the biotech field, reflecting heightened market interest in innovative drugs [2] Group 5: AI Integration - Eight departments jointly issued implementation opinions on "AI + Manufacturing," focusing on AI in drug development and medical supply chains, with a goal to cultivate 2-3 leading ecological enterprises by 2027 [2] - Century Securities highlighted the significant potential of AI in enhancing pharmaceutical manufacturing, particularly in drug discovery and intelligent diagnostics, which is expected to receive ongoing policy support and capital attention [2] Group 6: Index Composition - The index tracking the Hong Kong Stock Connect Innovative Drug sector includes major companies such as CSPC Pharmaceutical Group, BeiGene, and Innovent Biologics among its top ten weighted stocks [3]